4-phenylbutyric acid has been researched along with Brain Disorders in 3 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mangum, R | 1 |
| Soler-Alfonso, C | 1 |
| Birchansky, S | 1 |
| Stevens, A | 1 |
| Guiberson, NGL | 1 |
| Pineda, A | 1 |
| Abramov, D | 1 |
| Kharel, P | 1 |
| Carnazza, KE | 1 |
| Wragg, RT | 1 |
| Dittman, JS | 1 |
| Burré, J | 1 |
| Murray, LS | 1 |
| Lu, Y | 1 |
| Taggart, A | 1 |
| Van Regemorter, N | 1 |
| Vilain, C | 1 |
| Abramowicz, M | 1 |
| Kadler, KE | 1 |
| Van Agtmael, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for 4-phenylbutyric acid and Brain Disorders
| Article | Year |
|---|---|
Survival and Neurologic Recovery After Prompt Diagnosis and Aggressive Management of Severe Idiopathic Hyperammonemic Encephalopathy in a Patient with Acute Myeloid Leukemia.
Topics: Adult; Brain Diseases; Female; Humans; Hyperammonemia; Leukemia, Myeloid, Acute; Neurotoxicity Syndr | 2020 |
Mechanism-based rescue of Munc18-1 dysfunction in varied encephalopathies by chemical chaperones.
Topics: Animals; Brain Diseases; Caenorhabditis elegans Proteins; Cell Line, Tumor; Cells, Cultured; HEK293 | 2018 |
Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke.
Topics: Apoptosis; Basement Membrane; Brain Diseases; Cell Proliferation; Cells, Cultured; Collagen Type IV; | 2014 |